[Trial of "Huber Plus" in outpatients with chemotherapy by blood port system].
Gan To Kagaku Ryoho
; 35(3): 539-41, 2008 Mar.
Article
en Ja
| MEDLINE
| ID: mdl-18347413
ABSTRACT
We evaluated the advantages and disadvantages of Huber Plus through three outpatients treated with central venous (CV) port chemotherapy (FOLFOX). One of the three outpatients first received chemotherapy with safety huber (Huber Plus) in this study, and the huber needle was changed from non-safety to a safety huber (Huber Plus) in two of the three outpatients. All three outpatients were taught about needle removal methods and port care. In patients? education, 1) we used a skin model and training CV port, and 2) dressing materials were used as film dressing plus three-point fixation by Fixomull stretch. As a result, the safety system assured zero incidents. Moreover, the evaluation revealed that operability and pain of Huber Plus were not clinical problems. We suggest that Huber Plus is applicable in outpatient chemotherapy and that our care plan with patients? education might become a standard treatment.
Buscar en Google
Banco de datos:
MEDLINE
Asunto principal:
Pacientes Ambulatorios
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Bombas de Infusión Implantables
/
Neoplasias
Tipo de estudio:
Guideline
/
Prognostic_studies
Límite:
Humans
Idioma:
Ja
Año:
2008
Tipo del documento:
Article